Deutsche Bank’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-16,750
| Closed | -$804K | – | 4644 |
|
|
2020
Q1 | $804K | Sell |
16,750
-36,686
| -69% | -$1.71M | ﹤0.01% | 2218 |
|
|
2019
Q4 | $2.51M | Buy |
53,436
+17,857
| +50% | +$789K | ﹤0.01% | 1831 |
|
|
2019
Q3 | $839K | Sell |
35,579
-16,511
| -32% | -$489K | ﹤0.01% | 2398 |
|
|
2019
Q2 | $1.56M | Sell |
52,090
-145,651
| -74% | -$3.34M | ﹤0.01% | 2560 |
|
|
2019
Q1 | $4.43M | Buy |
197,741
+131,308
| +198% | +$2.82M | ﹤0.01% | 1944 |
|
|
2018
Q4 | $1.21M | Sell |
66,433
-30,830
| -32% | -$484K | ﹤0.01% | 2748 |
|
|
2018
Q3 | $1.76M | Buy |
97,263
+6,109
| +7% | +$72.4K | ﹤0.01% | 2945 |
|
|
2018
Q2 | $907K | Sell |
91,154
-134,798
| -60% | -$931K | ﹤0.01% | 3500 |
|
|
2018
Q1 | $1.2M | Buy |
225,952
+199,527
| +755% | +$1.43M | ﹤0.01% | 3199 |
|
|
2017
Q4 | $224K | Buy |
26,425
+921
| +4% | +$11.3K | ﹤0.01% | 3980 |
|
|
2017
Q3 | $370K | Sell |
25,504
-1,661
| -6% | -$25.1K | ﹤0.01% | 3569 |
|
|
2017
Q2 | $508K | Buy |
27,165
+8,682
| +47% | +$196K | ﹤0.01% | 3439 |
|
|
2017
Q1 | $392K | Sell |
18,483
-10,152
| -35% | -$194K | ﹤0.01% | 3220 |
|
|
2016
Q4 | $432K | Buy |
+28,635
| New | +$389K | ﹤0.01% | 3264 |
|
Other funds holding RARX
Deutsche Bank's RARX Position: Q2 2020 in Review
Deutsche Bank sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 16,750 shares — an estimated $804K sold.
Deutsche Bank first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $4.43M in Q1 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.
- Deutsche Bank reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
- Deutsche Bank sold 16,750 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $804K.
- Deutsche Bank first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
- Deutsche Bank's Ra Pharmaceuticals, Inc. Common Stock position peaked at $4.43M in Q1 2019.
- 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.
Based on Deutsche Bank's 13F filing for Q2 2020, filed 13 Aug 2020.